Publicacións nas que colabora con Ana Fernández Montes (10)
2023
2022
-
Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen
PLoS ONE, Vol. 17, Núm. 6 June
-
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Clinical and Translational Oncology, Vol. 24, Núm. 6, pp. 1209-1214
2021
-
Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain
BMC Cancer, Vol. 21, Núm. 1
-
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
Scientific Reports, Vol. 11, Núm. 1
2020
-
Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 351-359
-
First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study
Journal of Geriatric Oncology, Vol. 11, Núm. 8, pp. 1263-1267
2019
-
Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers
Cancer Medicine, Vol. 8, Núm. 3, pp. 882-889
2017
-
Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis
Journal of Cancer Research and Therapeutics, Vol. 13, Núm. 2, pp. 240-245
2013
-
Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: A retrospective study
Anticancer Research, Vol. 33, Núm. 9, pp. 4089-4096